InvestorsHub Logo
Followers 28
Posts 3152
Boards Moderated 0
Alias Born 10/04/2011

Re: None

Tuesday, 02/28/2012 3:15:32 PM

Tuesday, February 28, 2012 3:15:32 PM

Post# of 1036
More great news! I'm long on ALIM.

ALIMERA SCIENCES (ALIM) ILLUVIEN GETS POSITIVE EU NOD. COWEN KEEPS NEUTRAL

| S&P Marketscope
SNPMarketScopeViewsNews2012-02-28 15:01:10.000ALIMALIMERA SCIENCES, INC.STACY TROMBINOALIMERA SCIENCES (ALIM) ILLUVIEN GETS POSITIVE EU NOD. COWEN KEEPS NEUTRALAnalyst Simos Simeonidis says ALIM announces that European decentralized procedure was concluded with recommendation to approve Iluvien for treatment of chronic DME in 7 countries involved in the process. ALIM appears to be on step away from approval in these countries, which incl. 5 largest EU markets. Says final step should be completed by 3/28. Given run up in stock, uncertainty around financing, and reimbursement, launch and execution risks, and despite potential for upside to his ests, a takeout of co., sees risk/reward as balanced at current levels. S.Trombino|US;ALIM|2000013623|US|23783612
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALIM News